Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
The research laboratory of John C. Morris III, M.D., studies the potential utility of the thyroidal iodide transporter — the sodium/iodide symporter (NIS) — as a therapeutic gene for gene therapy. Prostate cancer is used as a model.
Dr. Morris has demonstrated this activity both in vitro and in vivo, and he's also shown that NIS expression can be induced by adenoviral-mediated gene transfer into prostate cancer xenografts. This uptake is sufficiently high that the tumors can be effectively treated with radioactive iodine, achieving as high as 80 percent complete responses.
Dr. Morris and his colleagues are currently conducting a phase I clinical trial of this therapy in men who have recurrent prostate cancer confined to the prostate bed. In addition, they are generating replication-competent virus vectors that express NIS to target metastatic and androgen-resistant prostate cancer.
The goal of Dr. Morris' work is to develop and apply a novel gene therapy approach to metastatic, hormone-resistant prostate cancer using radioactive as the therapeutic moiety.
Learn about clinical trials that address specific scientific questions about human health and disease.
See my studies.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.